Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | arachidonate 5-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | IPR001024,Lipoxygenase, LH2;IPR013819,Lipoxygenase, C-terminal,domain-containing | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | ko:K00461 arachidonate 5-lipoxygenase [EC1.13.11.34], putative | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0121 | 0.2475 | 0.2475 |
Schistosoma mansoni | lipoxygenase | 0.018 | 0.5712 | 0.5712 |
Echinococcus multilocularis | thymidylate synthase | 0.0121 | 0.2475 | 0.2475 |
Mycobacterium ulcerans | thymidylate synthase | 0.0121 | 0.2475 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0171 | 0.5217 | 0.5 |
Schistosoma mansoni | lipoxygenase | 0.0257 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0171 | 0.5217 | 0.5 |
Onchocerca volvulus | 0.0121 | 0.2475 | 1 | |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0171 | 0.5217 | 0.5 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0171 | 0.5217 | 0.5 |
Brugia malayi | thymidylate synthase | 0.0121 | 0.2475 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.0121 | 0.2475 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0121 | 0.2475 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0171 | 0.5217 | 0.5 |
Echinococcus granulosus | thymidylate synthase | 0.0121 | 0.2475 | 0.2475 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0171 | 0.5217 | 0.5 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0121 | 0.2475 | 0.5 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | 0.0257 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.18 uM | In vitro inhibitory activity against 5-lipoxygenase by reduction of LTB4 formed in guinea pig polymorphonuclear leukocytes (PMNs). | ChEMBL. | 8246226 |
IC50 (binding) | = 0.18 uM | In vitro inhibitory activity against 5-lipoxygenase by reduction of LTB4 formed in guinea pig polymorphonuclear leukocytes (PMNs). | ChEMBL. | 8246226 |
IC50 (binding) | = 0.83 uM | In vitro inhibitory activity against 5-lipoxygenase by reduction of 5-hydroxyeicosatetraenoic acid (5-HETE) formed in guinea pig polymorphonuclear leukocytes (PMNs). | ChEMBL. | 8246226 |
IC50 (binding) | = 0.83 uM | In vitro inhibitory activity against 5-lipoxygenase by reduction of 5-hydroxyeicosatetraenoic acid (5-HETE) formed in guinea pig polymorphonuclear leukocytes (PMNs). | ChEMBL. | 8246226 |
Inhibition (functional) | = % | Ex vivo inhibition of LTB-4 determined by measurement of A-23,187-stimulated LTB-4 production in dog blood at 3 mg/kg (p.o.); inactive | ChEMBL. | 8246226 |
Inhibition (functional) | = 0 % | Ex vivo inhibition of LTB-4 determined by measurement of A-23,187-stimulated LTB-4 production in dog blood at 3 mg/kg (p.o.); inactive | ChEMBL. | 8246226 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.